Savara Inc (SVRA) Stock Price & Analysis
Savara Inc (SVRA) fell 2.57% to USD 4.93 as of June 10, 2026 at 09:12 UTC, according to Nexqual real-time market data.
SVRA last closed at USD 5.06; the session ranged USD 4.73–5.05 on volume of 3,094,451 shares. Market capitalization is $1.01B, with a 52-week range of USD 1.98–7.01 (NMS). Source: Nexqual, June 10, 2026 at 09:12 UTC.
Key Statistics (as of June 10, 2026 at 09:12 UTC)
| Price | USD 4.93 |
|---|---|
| Change | ▼ 2.57% (down) |
| Previous Close | USD 5.06 |
| Open | USD 5.02 |
| Day Range | USD 4.73 – 5.05 |
| 52-Week Range | USD 1.98 – 7.01 |
| Volume | 3,094,451 shares |
| Market Cap | $1.01B |
| Exchange | NMS |
Technical Analysis (SVRA)
Nexqual's technical model rates SVRA "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 09:12 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.31 (neutral) |
| vs SMA50 | Below (USD 5.3) |
| MACD | -0.02 (negative) |
Analyst Ratings (SVRA)
Wall Street analysts rate SVRA "Strong Buy" based on 8 analysts, with a mean price target of USD 10.81 (range USD 9–16), per Nexqual as of June 10, 2026 at 09:12 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 10.81 |
| High Target | USD 16 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (SVRA)
| Next Earnings Date | 2026-05-13 |
|---|---|
| EPS Estimate | USD -0.15 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.13 vs est -0.12 ▼ miss |
| 2025-09-30 | USD -0.14 vs est -0.13 ▼ miss |
| 2025-06-30 | USD -0.14 vs est -0.12 ▼ miss |
Source: Nexqual, June 10, 2026 at 09:12 UTC.
Financials & Fundamentals (SVRA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -79.95% |
| Debt / Equity | 17.11 |
| Current Ratio | 13.47 |
| Total Cash | $204.14M |
| Total Debt | $30.11M |
| Free Cash Flow | $-57.65M |
Source: Nexqual, June 10, 2026 at 09:12 UTC.
Financial Health Score (SVRA)
Nexqual rates Savara Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 09:12 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $204M cash vs $30M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$107M |
| Efficiency | Critical — ROE -80%, ROA -40.5% |
Ownership (SVRA)
| Insider Ownership | +2.57% |
|---|---|
| Institutional Ownership | +104.25% |
| Shares Outstanding | 204.93M |
| Float | 130.12M |
| Short % of Float | +17.23% |
Source: Nexqual, June 10, 2026 at 09:12 UTC.
Leadership (SVRA)
Savara Inc is led by Matthew Pauls (age 54), Chairman & CEO, per Nexqual as of June 10, 2026 at 09:12 UTC.
| Chairman & CEO | Matthew Pauls (age 54) |
|---|---|
| Chief Financial & Administrative Officer and Secretary | David L. Lowrance (age 57) |
| Chief Operating Officer | Robert Matthew Lutz (age 56) |
| Executive Vice President of Global Medical Affairs | Brian Robinson |
| Executive Vice President of Global Technical Operations | Siddharth J. Advant |
Major Backers & Investors (SVRA)
Notable institutional backers of Savara Inc include NEA Management Company, LLC, Bain Capital Life Sciences Investors, LLC, Venrock Adviser, LLC, according to Nexqual as of June 10, 2026 at 09:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| NEA Management Company, LLC | 11.94% |
| Bain Capital Life Sciences Investors, LLC | 8.59% |
| Venrock Adviser, LLC | 6.71% |
| Deerfield Management Company, L.P | 6.62% |
| TCG Crossover Management, LLC | 6.03% |
| Frazier Life Sciences Management, L.P. | 4.74% |
| Polar Capital Holdings PLC | 4.66% |
| Nantahala Capital Management, LLC | 3.58% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.14% |
| Vanguard Group | 7.5% |
Source: Nexqual, June 10, 2026 at 09:12 UTC.
From Savara Inc's Latest SEC 10-K Filing (filed 2026-03-13)
Partnerships
- Below is a summary of some of the material risks associated with our business and investment in our securities.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AQST | Aquestive Therapeutics, Inc. | USD 3.99 | ▲ 1.53% |
| SLDB | Solid Biosciences Inc. | USD 6.57 | ▼ 1.94% |
| SYBX | Synlogic, Inc. | USD 0.64 | ▼ 7.25% |
| XERS | Xeris Biopharma Holdings, Inc. | USD 6.5 | ▲ 5.18% |
| MRKR | Marker Therapeutics, Inc. | USD 1.41 | ▼ 0.7% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:12 UTC. This page is informational and not investment advice.